ImmunoCellular Therapeutics, Ltd. filed its DRS on Feb 10, 2022 for the period ending Dec 31, 2020. In this report its auditor, Marcum LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1979 USD | 0.00% | 0.00% | -14.70% |
1st Jan change | Capi. | |
---|---|---|
-14.70% | 22.42M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IMUC Stock
- News EOM Pharmaceuticals Holdings, Inc.
- ImmunoCellular Therapeutics, Ltd. Auditor Raises 'Going Concern' Doubt